Australis Scientific

What Australis Scientific does

Australis Scientific is a Sydney-based medtech company developing wearable neuromodulation devices for the treatment of lower urinary tract symptoms, principally overactive bladder (OAB) and incontinence. Its flagship product, the Confidanz® Smart Patch, is a wearable medical device applied to the ankle that delivers electrical stimulation to manage OAB symptoms and connects to a companion smartphone application for at-home treatment, remote monitoring, and long-term symptom tracking. The device is currently an investigational product in clinical trials in Australia and has not yet received market authorization in Australia, USA, Japan, or any other geography.

The company pursues a clinical-regulatory pathway to commercialization, initially targeting healthcare providers and patients through clinical settings in Australia, with planned broader market entry via prescription. In November 2025, Australis Scientific secured a USD 6 million capital raise led by Japanese pharmaceutical company Rohto Pharmaceutical, with the partnership structured to leverage Rohto's pharmaceutical expertise and Asia Pacific distribution network for market entry — including a scheduled launch in China in June 2026. Total disclosed funding is approximately USD 9.3 million.

The business model centers on hardware device sales of the Confidanz Smart Patch through healthcare providers via prescription, with potential recurring revenue from the companion digital health application. The company is founder-led, with operations supported by a small team of 1-10 employees and a founding cohort that includes CEO Dr. Nicky Agahari, CTO Dr. Martin Jensen, COO/CFO Dr. Nigel Finch, CMO Dr. Danielle Delaney, and Chair of the Clinical Advisory Board Dr. Mihir Shanker. Recognition includes the MedTech Innovator Asia Pacific 2025 Grand Prize and the Harvard Innovation Challenge Grand Prize.

Name

Australis Scientific

Legal name

Australis Scientific Pty Ltd

Website

https://australisscientific.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Australis Scientific is a Sydney-based medtech startup developing the Confidanz® Smart Patch, a wearable ankle-applied neuromodulation device with smartphone connectivity that treats overactive bladder and incontinence. It is currently in clinical trials, targeting healthcare providers and patients via prescription across Australia and Asia Pacific via Rohto Pharmaceutical.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)

Keywords

• Neuromodulation devices
• Overactive bladder treatment
• Wearable medical devices
• Incontinence management
• Medical device development

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Hardware Device Sales: Revenue generated through sales of the Confidanz Smart Patch wearable medical device, sold directly to patients and through healthcare providers. The device is currently in clinical trials and has not yet received market authorization for sale in Australia, USA, Japan, or other geographies.
2. Digital Health Services: Potential recurring revenue from the companion smartphone application and associated digital health services for treatment management, remote monitoring, and long-term symptom tracking.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Australis Scientific is a Sydney-based medtech company developing the Confidanz Smart Patch, a wearable neuromodulation device applied to the ankle that delivers electrical stimulation to manage overactive bladder and incontinence symptoms. The patch pairs with a companion smartphone application for at-home treatment, remote monitoring, and long-term symptom tracking. The product is currently an investigational device being evaluated in clinical trials and has not yet received market authorization for commercial sale in Australia, USA, Japan, or other geographies.

Product overview

Australis Scientific is a medtech company developing neuromodulation devices, with Confidanz® Smart Patch as its flagship product. The company operates with a single-product focused architecture, targeting overactive bladder and incontinence treatment. Confidanz® Smart Patch is an investigational device currently being used in clinical trials and has not received market authorisation for sale in Australia, USA, Japan, or other geography. The company is expanding into Asian markets with support from partner Rohto Pharmaceutical.

Differentiator

Problem solved

Functional benefit

Brands

• Confidanz® Smart Patch: Australis Scientific's flagship device for minimally invasive overactive bladder management, providing patients with control and comfort through neuromodulation technology.

Products and services

• Confidanz Smart Patch The Confidanz Smart Patch is a wearable neuromodulation device applied to the ankle that delivers electrical stimulation to manage overactive bladder and incontinence symptoms. It is designed as a minimally invasive, patient-controlled treatment for adults suffering from OAB, with a companion smartphone application enabling at-home therapy, remote monitoring, and long-term symptom tracking. It is intended for distribution via prescription through healthcare providers and is currently an investigational device limited to clinical trial use.

Quantifiable outcome

• The Confidanz Smart Patch has demonstrated efficacy in managing overactive bladder symptoms through neuromodulation therapy, though specific clinical outcome data is still being collected in ongoing clinical trials.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• CVRx: Public neuromodulation company with the Barostim system for heart failure. Operates broadly in therapeutic neuromodulation with regulatory and clinical infrastructure expertise transferable to OAB applications, making it a relevant comparable for the neuromodulation business model.
• Laborie Medical Technologies: Acquired Cogentix Medical and owns the Urgent PC percutaneous tibial nerve stimulation system for OAB, making it a broad incumbent in OAB neuromodulation and urology diagnostics. Competes for the same clinician and patient channels as Australis.
• Medtronic: Dominant incumbent in sacral nerve stimulation for OAB through its InterStim franchise, with established reimbursement, sales infrastructure, and physician relationships. Australis must displace or differentiate against Medtronic's entrenched InterStim platform in the same therapeutic indication.

Emerging players

• Elidah: Maker of Elitone, a wearable external stimulation device for female stress urinary incontinence. An emerging player targeting the same at-home, non-invasive incontinence treatment use case as Australis, with overlapping patient demographic.
• Neuspera Medical: Develops miniaturized, wirelessly powered neuromodulation implants across multiple indications. Shares the neuromodulation technology DNA with Australis, including the pursuit of smaller, less invasive form factors, though currently focused on implantable sacral and peripheral nerve targets.

Direct peers

• InControl Medical: Sells the ApexM and similar at-home electrical stimulation devices for incontinence and pelvic floor disorders. Direct competitor targeting the same at-home, non-invasive treatment positioning as Confidanz Smart Patch.
• Axonics: Directly competes in OAB neuromodulation with its sacral neuromodulation (SNM) implant system (r-SNM). Both target the same overactive bladder patient population with electrical nerve stimulation therapy, though Axonics uses an implantable approach while Australis uses an external ankle patch.
• BlueWind Medical: Develops the REVIVO peripheral tibial nerve stimulation system for OAB, conceptually the closest analog to Confidanz: a less-invasive, externally worn neuromodulation alternative to sacral implants. Targets the same OAB patient seeking non-surgical treatment.
• Valencia Technologies: Markets the eCoin peripheral neurostimulator, a minimally invasive tibial nerve stimulator for urge incontinence. Directly comparable mechanism and indication to Confidanz, positioned as a smaller, less invasive alternative to sacral implants.

Others

• Inspire Medical Systems: Public neuromodulation company with hypoglossal nerve stimulation for sleep apnea. Not a direct OAB competitor, but a relevant comparable demonstrating the path from early-stage neuromodulation startup to scaled commercial franchise in an adjacent therapeutic area.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/australisscientific
• Instagraminstagram.com/australisscientific

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Australis Scientific